132646-46-9

Upstream product

• 76-83-5 trityl chloride 
• 141109-85-5 5-<(4-hydroxyphenyl)methyl>-2,4-oxazolidinedione 
• 39720-27-9 4-acetoxybenzyl chloride 
• 132646-26-5 3-Triphenylmethyl-1,3-oxazolidine-2,4-dione 

Downstream Products

• 132646-48-1 N-(triphenylmethyl)-5-<4-<2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy>benzyl>-2,4-oxazolidinedione 
• 132646-51-6 5-(4-{2-[2-(3,5-Bis-trifluoromethyl-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-benzyl)-oxazolidine-2,4-dione 
• 132646-54-9 5-{4-[2-(5-Methyl-2-naphthalen-2-yl-thiazol-4-yl)-ethoxy]-benzyl}-oxazolidine-2,4-dione 
• 136058-59-8 5-{4-[2-(2-Cyclohexyl-5-methyl-oxazol-4-yl)-ethoxy]-benzyl}-oxazolidine-2,4-dione 

Relevant academic research and scientific papers

Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives

Novel thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives, process for their manufacture, pharmaceutical preparations containing them and the use of the compounds in conditions associated with insulin resistance.

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.